Table I.
Groups | Apoptotic cells | p-Akt-positive cells | p-Akt |
---|---|---|---|
Control group | 7.23±1.05 | 21.41±1.20 | 0.398±0.064 |
Model group | 26.72±3.53a | 26.57±2.46a | 0.528±0.044a |
rHuEpo treated group | 16.59±1.12a–c | 54.81±5.08a–c | 0.759±0.027a–c |
LY294002 treated group | 21.08±2.67a,b | 33.07±4.87a,b | 0.64±0.012a,b |
LY294002 control group | 17.47±1.86a–c | 52.35±4.63a–c | 0.756±0.027a–c |
F-value | 19.19 | 28.77 | 15.70 |
P-value | <0.05 | <0.05 | <0.01 |
P<0.05, control group vs. model, rHuEpo treated, LY294002 treated, LY294002 control groups
P<0.05, model group vs. rHuEpo treated, LY294002 treated, LY294002 control groups
P<0.05, LY294002 treated group vs. rHuEpo treated, LY294002 control groups. No significant difference was found between rHuEpo treated group and LY294002 control group. rHuEpo, recombinant human erythropoietin.